258 related articles for article (PubMed ID: 28677529)
1. Generation and characterization of a human iPSC cell line expressing inducible Cas9 in the "safe harbor" AAVS1 locus.
Castaño J; Bueno C; Jiménez-Delgado S; Roca-Ho H; Fraga MF; Fernandez AF; Nakanishi M; Torres-Ruiz R; Rodríguez-Perales S; Menéndez P
Stem Cell Res; 2017 May; 21():137-140. PubMed ID: 28677529
[TBL] [Abstract][Full Text] [Related]
2. Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.
Thamodaran V; Rani S; Velayudhan SR
Methods Mol Biol; 2022; 2454():755-773. PubMed ID: 33830454
[TBL] [Abstract][Full Text] [Related]
3. Differential Transgene Silencing of Myeloid-Specific Promoters in the
Klatt D; Cheng E; Hoffmann D; Santilli G; Thrasher AJ; Brendel C; Schambach A
Hum Gene Ther; 2020 Feb; 31(3-4):199-210. PubMed ID: 31773990
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-Based Safe-Harbor Gene Editing in Rhesus iPSCs.
Yada RC; Ostrominski JW; Tunc I; Hong SG; Zou J; Dunbar CE
Curr Protoc Stem Cell Biol; 2017 Nov; 43():5A.11.1-5A.11.14. PubMed ID: 29140568
[TBL] [Abstract][Full Text] [Related]
5. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
6. Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers.
Hong SG; Yada RC; Choi K; Carpentier A; Liang TJ; Merling RK; Sweeney CL; Malech HL; Jung M; Corat MAF; AlJanahi AA; Lin Y; Liu H; Tunc I; Wang X; Palisoc M; Pittaluga S; Boehm M; Winkler T; Zou J; Dunbar CE
Mol Ther; 2017 Jan; 25(1):44-53. PubMed ID: 28129126
[TBL] [Abstract][Full Text] [Related]
7. A Doxycycline-Inducible System for Genetic Correction of iPSC Disease Models.
Sim X; Cardenas-Diaz FL; French DL; Gadue P
Methods Mol Biol; 2016; 1353():13-23. PubMed ID: 25630922
[TBL] [Abstract][Full Text] [Related]
8. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology.
Estève J; Blouin JM; Lalanne M; Azzi-Martin L; Dubus P; Bidet A; Harambat J; Llanas B; Moranvillier I; Bedel A; Moreau-Gaudry F; Richard E
Biochem Biophys Res Commun; 2019 Oct; 517(4):677-683. PubMed ID: 31402115
[TBL] [Abstract][Full Text] [Related]
9. Variable expression and silencing of CRISPR-Cas9 targeted transgenes identifies the
Bhagwan JR; Collins E; Mosqueira D; Bakar M; Johnson BB; Thompson A; Smith JGW; Denning C
F1000Res; 2019; 8():1911. PubMed ID: 32789000
[No Abstract] [Full Text] [Related]
10. Targeting the AAVS1 Site by CRISPR/Cas9 with an Inducible Transgene Cassette for the Neuronal Differentiation of Human Pluripotent Stem Cells.
Gu J; Rollo B; Sumer H; Cromer B
Methods Mol Biol; 2022; 2495():99-114. PubMed ID: 35696030
[TBL] [Abstract][Full Text] [Related]
11. Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies.
Wang G; Yang L; Grishin D; Rios X; Ye LY; Hu Y; Li K; Zhang D; Church GM; Pu WT
Nat Protoc; 2017 Jan; 12(1):88-103. PubMed ID: 27929521
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
Dannenmann B; Nasri M; Welte K; Skokowa J
Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
[TBL] [Abstract][Full Text] [Related]
13. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
14. Conditional gene knockout and reconstitution in human iPSCs with an inducible Cas9 system.
Wu M; Liu S; Gao Y; Bai H; Machairaki V; Li G; Chen T; Cheng L
Stem Cell Res; 2018 May; 29():6-14. PubMed ID: 29554589
[TBL] [Abstract][Full Text] [Related]
15. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 system and its applications in human hematopoietic cells.
Hu X
Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
[TBL] [Abstract][Full Text] [Related]
17. Generation of an Induced Pluripotent Stem Cell Line with the Constitutive EGFP Reporter.
Butterfield KT; McGrath PS; Han CM; Kogut I; Bilousova G
Methods Mol Biol; 2020; 2155():11-21. PubMed ID: 32474864
[TBL] [Abstract][Full Text] [Related]
18. A Tet-Inducible CRISPR Platform for High-Fidelity Editing of Human Pluripotent Stem Cells.
Jurlina SL; Jones MK; Agarwal D; De La Toba DV; Kambli N; Su F; Martin HM; Anderson R; Wong RM; Seid J; Attaluri SV; Chow M; Wahlin KJ
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553630
[TBL] [Abstract][Full Text] [Related]
19. Efficient differentiation of cardiomyocytes and generation of calcium-sensor reporter lines from nonhuman primate iPSCs.
Lin Y; Liu H; Klein M; Ostrominski J; Hong SG; Yada RC; Chen G; Navarengom K; Schwartzbeck R; San H; Yu ZX; Liu C; Linask K; Beers J; Qiu L; Dunbar CE; Boehm M; Zou J
Sci Rep; 2018 Apr; 8(1):5907. PubMed ID: 29651156
[TBL] [Abstract][Full Text] [Related]
20. Targeted transgene insertion into the AAVS1 locus driven by baculoviral vector-mediated zinc finger nuclease expression in human-induced pluripotent stem cells.
Tay FC; Tan WK; Goh SL; Ramachandra CJ; Lau CH; Zhu H; Chen C; Du S; Phang RZ; Shahbazi M; Fan W; Wang S
J Gene Med; 2013 Oct; 15(10):384-95. PubMed ID: 24105820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
